164 related articles for article (PubMed ID: 32728967)
1. Anatomic and Functional Imaging of Neuroendocrine Tumors.
Morse B; Al-Toubah T; Montilla-Soler J
Curr Treat Options Oncol; 2020 Jul; 21(9):75. PubMed ID: 32728967
[TBL] [Abstract][Full Text] [Related]
2. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
5. Multimodality Imaging of Neuroendocrine Tumors.
Galgano SJ; Sharbidre K; Morgan DE
Radiol Clin North Am; 2020 Nov; 58(6):1147-1159. PubMed ID: 33040854
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTATATE PET/MRI for Neuroendocrine Tumors: A Pictorial Review.
Nguyen NC; Moon CH; Muthukrishnan A; Furlan A
Clin Nucl Med; 2020 Sep; 45(9):e406-e410. PubMed ID: 32520493
[TBL] [Abstract][Full Text] [Related]
7. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
8. Standard imaging techniques for neuroendocrine tumors.
Bushnell DL; Baum RP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):153-62, ix. PubMed ID: 21349416
[TBL] [Abstract][Full Text] [Related]
9. [Imaging and radioguided surgery of tumors NETs].
Schillirò F; Mallardo V; Manna A; Fontanarosa A; Califano T; Della Vecchia N; Romano G; Di Crescenzo V; Genovese EA
Recenti Prog Med; 2013; 104(7-8):336-9. PubMed ID: 24042403
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumors: Imaging of Treatment and Follow-up.
Migut AE; Kaur H; Avritscher R
Radiol Clin North Am; 2020 Nov; 58(6):1161-1171. PubMed ID: 33040855
[TBL] [Abstract][Full Text] [Related]
11. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
12. Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings.
Baghdadi A; Ghadimi M; Mirpour S; Hazhirkarzar B; Motaghi M; Pawlik TM; Kamel IR
Surg Oncol; 2021 Jun; 37():101529. PubMed ID: 33549952
[TBL] [Abstract][Full Text] [Related]
13. [Gastroenteropancreatic endocrine tumors].
Schmid-Tannwald C; Schmid-Tannwald CM; Reiser MF; Berger F
Radiologe; 2014 Oct; 54(10):989-97. PubMed ID: 25234769
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
[TBL] [Abstract][Full Text] [Related]
15. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
16. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls.
Yu R; Wachsman A
Endocrinol Metab Clin North Am; 2017 Sep; 46(3):795-814. PubMed ID: 28760239
[TBL] [Abstract][Full Text] [Related]
17. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Sadowski SM; Millo C; Neychev V; Aufforth R; Keutgen X; Glanville J; Alimchandani M; Nilubol N; Herscovitch P; Quezado M; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
20. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]